Chiron slashes flu vaccine production forecast

Share this article:

Chiron Corp., one of only two major makers of the flu vaccine for the United States, cut its 2005 output forecast due to continuing problems with its Liverpool, England, factory.

The company plans to produce 18 million to 26 million doses of the Fluvirin vaccine for the upcoming season. It previously forecast making 25 million to 30 million doses.

Last year, Chiron failed to ship 50 million shots to the U.S., prompting a vaccine shortage and concerns about the most vulnerable receiving shots. The British government shut down the facility on Oct. 5 after Chiron discovered 4 million tainted flu shots.

GlaxoSmithKline could sell as many as 10 million flu shots in the U.S. this flu season, pending Food and Drug Administration approval of its marketing application. Sanofi is expected to supply 60 million shots and MedImmune Inc. of Gaithersburg, MD, is expected to provide 3 million doses of its nasal spray vaccine.

Share this article:

More in News

Long-term care continues to lead in deal volume and value: PwC report

Long-term care continues to lead in deal volume ...

Long-term care bucked healthcare industry trends with strong merger and acquisition activity in the second quarter of 2014, according to newly released data from professional services firm PricewaterhouseCoopers.

Empowering nurse practitioners could reduce hospitalizations from SNFs, study finds

Granting more authority to nurse practitioners is associated with reduced hospitalization of skilled nursing facility residents, according to recently published findings.

Pioneer ACO drops out of program, despite reductions in skilled nursing utilization

A California healthcare system has become the latest dropout from the Pioneer Accountable Care Organization program, despite reducing skilled nursing facility utilization and improving its readmission rates. Sharp HealthCare announced its decision in a quarterly financial statement released Tuesday.